BCRX - What's Going On With BioCryst Stock After Earnings? | Benzinga
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell.
The Details:
BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share from the same period last year.
The company reported quarterly sales of $93.4 million which beat the analyst consensus estimate of $90.01 million by 3.77% and is a 17.42% increase over sales of $79.55 million from the prior year's quarter.
BioCryst sees fiscal year 2024 Orladeyo net revenue of between $380 million and $400 million. The company said that it expects an operating profit in 2024 and to ...